Abstract:Rationale: Cancer continues to be a significant public health issue. Traditional treatments such as surgery, radiotherapy, and chemotherapy often fall short because of intrinsic issues such as lack of specificity and poor drug delivery, leading to insufficient drug concentration at the tumor site and/or potential side effects. Consequently, improving the delivery of conventional chemotherapy drugs like doxorubicin (DOX) is crucial for their therapeutic efficacy. Successful cancer treatment is achieved when regulated cell death (RCD) of cancer cells, which includes apoptotic and non-apoptotic processes such as ferroptosis, is fundamental to successful cancer treatment. The developing field of nanozymes holds considerable promise for innovative cancer treatment approaches. Methods: A dual-metallic nanozyme system encapsulated with DOX was created, derived from metal-organic frameworks (MOFs), designed to combat tumors by depleting glutathione (GSH) and concurrently liberating DOX. The initial phase of the study examined the GSH oxidase-mimicking function of the dimetallic nanozyme (ZIF-8/SrSe) through enzyme kinetic assays and Density Functional Theory (DFT) simulations. Following this, we probed the ability of ZIF-8/SrSe@DOX to release DOX in response to the tumor microenvironment in vitro, alongside examining its anticancer capabilities and mechanisms prompting apoptosis or ferroptosis in cancer cells. Moreover, we established tumor-bearing animal models to corroborate the anti-tumor effectiveness of our nanozyme complex and to identify the involved apoptotic and ferroptotic pathways implicated. Results: Enzyme kinetic analyses demonstrated that the ZIF-8/SrSe nanozyme exhibits substantial GSH oxidase-like activity, effectively oxidizing reduced GSH to glutathione disulfide (GSSG), while also inhibiting glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11). This inhibition led to an imbalance in iron homeostasis, pronounced caspase activation, and subsequent induction of apoptosis and ferroptosis in tumor cells. Additionally, the ZIF-8/SrSe@DOX nanoparticles efficiently delivered DOX, causing DNA damage and further promoting apoptotic and ferroptotic pathways. Conclusions: This research outlines the design of a novel platform that combines chemotherapeutic agents with a Fenton reaction catalyst, offering a promising strategy for cancer therapy that leverages the synergistic effects of apoptosis and ferroptosis.

Dual-functional Se/Fe Complex Facilitates TRAIL Treatment Against Resistant Tumor Cells Via Modulating Cellular Endoplasmic Reticulum Stress

Anti-recurrence/metastasis and chemosensitization therapy with thioredoxin reductase-interfering drug delivery system

Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Multifunctional Sr/Se co-doped ZIF-8 nanozyme for chemo/chemodynamic synergistic tumor therapy via apoptosis and ferroptosis

Dual Targeting of Endoplasmic Reticulum by Redox-Deubiquitination Regulation for Cancer Therapy

Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression.

Trail-Armed Er Nanosomes Induce Drastically Enhanced Apoptosis In Resistant Tumor In Combination With The Antagonist Of Iaps (Azd5582)

Tumor Microenvironment Specific Regulation Ca‐Fe‐Nanospheres for Ferroptosis‐Promoted Domino Synergistic Therapy and Tumor Immune Response

Targeting Death Receptors for Drug-Resistant Cancer Therapy: Codelivery of Ptrail and Monensin Using Dual-Targeting and Stimuli-Responsive Self-Assembling Nanocomposites

Selenium-containing metallodrug overcomes cervical cancer radioresistance by physical-chemical dual sensitization

Enhanced Apoptosis: TRAIL‐Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582) (adv. Healthcare Mater. 11/2021)

Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo

Selenium-driven enhancement of synergistic cancer chemo-/radiotherapy by targeting nanotherapeutics

Combination of long-acting TRAIL and tumor cell-targeted photodynamic therapy as a novel strategy to overcome chemotherapeutic multidrug resistance and TRAIL resistance of colorectal cancer

SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer

Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: the Activation of the ASK1-ERK-Sp1 Pathway

Multi-Enzyme Cascade-Triggered Nitric Oxide Release Nanoplatform Combined with Chemo Starvation-like Therapy for Multidrug-Resistant Cancers

Tumor microenvironments self-activated nanoscale metal-organic frameworks for ferroptosis based cancer chemodynamic/photothermal/chemo therapy

Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors

Tumor Microenvironment-Activatable Fe-doxorubicin Preloaded Amorphous CaCO3 Nanoformulation Triggers Ferroptosis in Target Tumor Cells

A homologous membrane-camouflaged self-assembled nanodrug for synergistic antitumor therapy